Landos has filed to go public after a phase 2 trial of its Virginia Tech-invented IBD treatment produced favourable results this month.

Landos Biopharma, a US-based autoimmune disease therapeutics developer exploiting Virginia Tech research, has filed for a $100m initial public offering. Founded in 2017, the spinout has been working on a small molecule-based drug called BT-11 to treat autoimmune and inflammatory problems associated with two forms of inflammatory bowel disease (IBD): Crohn’s disease and ulcerative colitis.…

The rest of this content is only accessible to University Venturing: News, Data and Events - Global University Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.